Dexcom selected as first participant in FDA's TEMPO pilot
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/18/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
Dexcom Announced as First Participant Selected for FDA's TEMPO Digital Health Devices Pilot Program
July 22, 2026 5:15 PM EDTParticipation advances the companys vision and regulatory pathway for earlier intervention, screening for prediabetes and Type 2 diabetes and empowerment
SAN DIEGO--(BUSINESS WIRE)-- Dexcom (NASDAQ: DXCM), the global leader in glucose biosensing, today announced it is the first company selected by the U.S. Food and Drug Administration (FDA) to participate in the Technology-Enabled Meaningful Patient Outcomes (TEMPO) Pilot Program, a first-of-its-kind initiative designed to evaluate innovative digital health technologies that improve chronic disease management while generating real-world evidence.
This press release features multimedia. View the full release... More
